In this study, we aimed to examine the clinical usefulness of their new biomarkers in addition to conventional markers, such as urinary albumin and urinary N-acetyl-β-D-glucosaminidase (NAG), in post-TAVI AKI. This evidence concerns the gene ALB and acute kidney injury.